Epithelial Ovarian Cancer
Conditions
Interventions
test group:omprehensive staged surgery + HIPECC (3times)+ postoperative systemic chemotherapy (6weeks)
Control group:Comprehensive staged surgery + postoperative systemic chemotherapy (6weeks)
Sponsors
The Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. In the initial treatment, no chemotherapy, radiotherapy or other anti-tumor treatment is available before the start of the clinical trial; 2. Aged 18 to 70 years; 3. Non-pregnant, lactating women; 4. Imaging (full abdominal enhanced CT or ultrasound) is highly suggestive of ovarian malignancies, CA125 > 300U/mL and / or ascites to find cancer cells; 5. Intraoperative frozen pathology report: epithelial ovarian cancer, the visual stage is between IC1-IIIB, feasible full-stage surgery; 6. The bone marrow reserve function is good, and the blood routine meets the following conditions: white blood cell count >= 3.5x10^9/L, neutrophils >= 1.5x10^9/L, platelet count >= 100x10^9/L, hemoglobin >= 90 g/L; 7. Organ function is good, biochemical examination meets the following conditions: ALT <= 2.5 x upper limit of normal value (ULN), AST <= 2.5 x ULN, serum total bilirubin <= 1.5 x ULN, serum creatinine <= 1.5 × ULN; 8. Functional status: 0-1 (ECOG); 9. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Have a history of other malignant tumors within 5 years; 2. Intraoperative frozen pathology is reported as non-epithelial ovarian cancer, or epithelial ovarian cancer staging outside of IC1-IIIB; 3. At the same time, there are serious or uncontrolled medical diseases and infected people (including atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction below 50%, difficult to control high blood pressure, etc.); 4. Patients with seizures requiring treatment (eg steroids or antiepileptic treatment); 5. Patients with severe or uncontrolled mental illness; 6. Drug abuse and medical, psychological or social conditions may interfere with the patient's participation in the study or have an impact on the evaluation of the research results; 7. Any unstable condition or condition that may jeopardize patient safety and compliance; 8. Anticancer drug treatment in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease-free survival (DFS);safety; | — |
Countries
China
Contacts
Public ContactHui Zhang
The Fourth Hospital of Hebei Medical University
Outcome results
None listed